Immune Hemolytic Anemia and Renal Failure Due to Teniposide
1982; Massachusetts Medical Society; Volume: 306; Issue: 18 Linguagem: Inglês
10.1056/nejm198205063061806
ISSN1533-4406
AutoresB. Habibi, M. Lopez, M Serdaru, A Baumelou, Marcel Vonlanthen, R Marteau, Charles T. Salmon,
Tópico(s)Blood disorders and treatments
ResumoTENIPOSIDE (VM 26) is a semisynthetic derivative of podophyllotoxin (molecular weight, 657 daltons) that has been used for a decade in cancer chemotherapy, especially in lymphoma and brain tumors. The drug has been reported to cause anaphylactic reactions of unknown origin.1 This paper describes clinical and immunohematologic features of an antibody to teniposide that causes acute hemolysis and renal failure.Case HistoryTeniposide therapy was initiated in a 47-year-old man who had a relapse a few months after removal of a brain tumor. The drug was given monthly at a dose of 100 mg per day on Days 1 and . . .
Referência(s)